The need to find novel strategies to speed orphan drug development is driven by the current problems of limited resources, disease severity, restricted patient access, and a lack of understanding about rare diseases. Manufacturers are required to scale manufacturing to treat rare/orphan diseases by the 1983 Orphan Drug Act (ODA), which has caused a significant improvement in the orphan drug market. To meet patients' unmet requirements, it is crucial to develop novel medicines for these rare diseases.
The 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference, scheduled for October 9–10 in London, aims to offer an insightful and inclusive forum for discussion of recent developments in the creation of life-saving treatments, pressing problems and plans to accelerate orphan drug development in the near future. To help shape current and upcoming challenges in drug analysis, the conference will bring together scientists, researchers, entrepreneurs, academicians, medical officials, and technologists from all over the world to discuss the most recent findings in the fields of rare diseases and orphan drugs. It offers attendees the ability to network with colleagues in the business, take part in this scientific conference, and remain up to date on the most recent advancements in the research of rare diseases.
To know more details about the combined packages and offers at the Co-located events write to us at events@marketsandmarkets.com.